Khondrion, the Dutch biopharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, announces today the successful completion of its Phase 1 Clinical trials with its lead compound KH176. KH176 is an orally bio-‐available small molecule developed by Khondrion for the treatment of mitochondrial (-‐related) diseases. The compound is a member of a new class of Khondrion drugs essential for the control of oxidative and redox pathologies. The Phase 1 Clinical trials, performed in healthy male volunteers, consisted of single ascending and multiple dosing arms both randomized, placebo controlled and double-‐blinded. The study deemed that KH176 is well tolerated and has an excellent pharmacokinetic profile.
Jan Smeitink, Khondrion’s CEO and Professor of Mitochondrial Medicine at the Radboud University Medical Center, Nijmegen, The Netherlands, said “With the successful outcome of the KH176 Phase I Clinical trials we have set an important step to accomplish our mission – making a substantial contribution to the development of drugs for patients suffering from mitochondrial diseases”.
Khondrion expects to initiate randomized, placebo-‐controlled, double-‐blinded Phase II Clinical trials in 2016.
More information: www.khondrion.com